Daiichi Sankyo to license a subcutaneous version of Enhertu (fam -trastuzumab deruxtecan) from Alteogen
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be forthcoming from Alteogen following a licensing deal worth up to $300 million.
Under the deal, Daiichi will pay Alteogen $20 million upfront to develop the subcutaneous (SC) Enhertu formulation using its human hyaluronidase (ALT-B4) platform, according to a Korean exchange disclosure. Commercial and development milestones could add up to another $280 million for Alteogen, plus royalties tied to sales. The contract is conditional and “may vary” based on the success of clinical studies and regulatory approval.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins